title: Role of spinal serotonin 5-HT2A receptor in 2',3'-dideoxycytidine-induced neuropathic pain in the rat and the mouse.
abstract: Several lines of evidence suggest that descending serotoninergic facilitatory pathways are involved in neuropathic pain. These pathways may involve 5-HT2A receptors known to play a role in spinal and peripheral sensitization. The implication of this receptor in neuropathy was investigated in a model of peripheral neuropathy induced by 2',3'-dideoxycytidine, a nucleoside analogue with reverse transcriptase inhibitory properties used in HIV/AIDS therapy. Four days after a single 100mg/kg i.v. administration in the tail vein, mitochondrial alterations in nociceptive and non-nociceptive dorsal root ganglion cells were observed at the lumbar level. These alterations were not associated with TUNEL labelling or with modification of the total number of dorsal root ganglion cells. At the same time point, 5-HT2A receptor immunolabelling was increased throughout the dorsal horn (by 49.5% in layer II and 57.8% in layer III). The number of 5-HT2A receptor immunoreactive neurons in the dorsal root ganglion was also increased by 30.7%. Four days after 2',3'-dideoxycytidine administration, rats had developed thermal allodynia as well as mechanical hyperalgesia and allodynia, which dose-dependently decreased after epidural injection of MDL 11,939, a 5-HT2A receptor antagonist. Moreover, 5-HT2A receptor knock-out mice did not develop 2',3'-dideoxycytidine-induced neuropathy whereas their control littermates displayed a neuropathy comparable to that observed in rats. Our data show that 2',3'-dideoxycytidine-induced neuropathy is associated with alterations of nociceptive and non-nociceptive peripheral cells and that the 5-HT2A receptor is involved in the peripheral sensitization of nociceptors as well as in a wide central sensitization of dorsal horn neurons.
authors: Neurobiologie des Signaux Intercellulaires, CNRS, UMR 7101, Université Pierre et Marie Curie, 7 Quai St Bernard, 75252 Paris cedex 05, France INSERM UMR 677, Université Pierre et Marie Curie-Paris 6, Faculté de Médecine, site Pitié-Salpêtrière, 91 boulevard de l'Hôpital, 75634 Paris cedex 13, France Department of Psychiatry, Columbia University, New York, NY 10032, USA.
authors: Juliette
authors: J
authors: Van Steenwinckel
authors: Marie-Jeanne
authors: MJ
authors: Brisorgueil
authors: Jacqueline
authors: J
authors: Fischer
authors: Daniel
authors: D
authors: Vergé
authors: Jay A
authors: JA
authors: Gingrich
authors: Sylvie
authors: S
authors: Bourgoin
authors: Michel
authors: M
authors: Hamon
authors: Rozenn
authors: R
authors: Bernard
authors: Marie
authors: M
authors: Conrath
mesh_terms: D000818:Animals; D005727:Ganglia, Spinal / Q000187:drug effects / Q000502:physiology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009437:Neuralgia / Q000139:chemically induced / Q000235:genetics / Q000503:physiopathology*; D009619:Nociceptors / Q000502:physiology; D010523:Peripheral Nervous System Diseases / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D044402:Receptor, Serotonin, 5-HT2A / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D013045:Species Specificity; D013116:Spinal Cord / Q000187:drug effects / Q000502:physiology*; D016047:Zalcitabine / Q000633:toxicity*
chemical_list: D044402:Receptor, Serotonin, 5-HT2A; D016047:Zalcitabine